Altimmune to Participate at Two Upcoming Investor Conferences

May 7, 2024 at 7:30 AM EDT

GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

  • JMP Life Sciences Conference (New York, NY)
    Tuesday, May 14, 2024
    Fireside Chat at 9:00 a.m. Eastern Time
  • UBS Obesity Therapeutics Day (Virtual Conference)
    Thursday, May 23, 2024
    Fireside Chat at 10:00 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt                                                        
Chief Financial Officer                                                 
Phone: 240-654-1450                                               

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
Julia Weilman
Burns McClellan
Phone: 646-732-4443

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657 

Primary Logo

Source: Altimmune, Inc


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail